Fondaparinux

For an informed discussion with your doctor or pharmacist. This information collection is not a clinically validated interaction checker. Missing data do not establish safety. Do not change or stop prescribed medicines on the basis of this information. The findings apply to the specific conditions studied; laboratory and animal studies cannot be directly extrapolated to humans.

Active substance: Fondaparinux

Examples of brand names: Arixtra [EU/DE]

ATC code: B01AX05

Main use (for orientation): Anticoagulation

Documented research summary

No direct finding for the pair. General cannabinoid CYP inhibition does not automatically establish an increase in concentrations here.

Uncertainties and limitations

General coagulation warnings do not replace evidence of a combination effect.

No data found does not mean a safe combination.

Research is limited to the specified date and protocol; it is not globally exhaustive. Brand names and authorisations do not constitute a complete current market overview.

Structured assessment

Category: Drug context

Cannabinoid scope: 28 register names in the documented search family; neither 28 individual clinical trials nor a blanket assessment of all cannabinoids.

Evidence status: Insufficient pair-specific data

Mechanism / drug context: Fondaparinux is largely excreted unchanged renally; no principal CYP-mediated breakdown.

Type of supporting material: Medicine information and documented individual review; no positive pair trial

Clinical interpretation: Requires individual assessment by a doctor or pharmacist. Lack of evidence does not establish safety; no dosage or discontinuation advice is provided.

Context: Fondaparinux sodium injection, Zydus, US label dated 28 October 2025: contraindications, sections 7 and 12.1–12.4 read. Selective antithrombin-mediated factor Xa inhibition; mainly excreted unchanged in urine. Minor in vitro CYP inhibition; no substantial CYP-mediated perpetrator interaction expected according to the label. Severe renal impairment and bleeding risk are important.

Drug context and gaps in search results are not measured interactions. The source role below describes which statement the source actually supports.

Source role [RLABEL_D0016]: Drug context

Statement supported: Supports dosage form, metabolism and/or known risks; alone, it does not substantiate a cannabinoid–drug pair finding.

Source: FONDAPARINUX SODIUM INJECTION, SOLUTION [ZYDUS PHARMACEUTICALS (USA) INC.] [RLABEL_D0016]

Scope of review: Individual research with documented title/abstract screening and targeted review of original sections. This is not exhaustive evidence that interactions are absent.

Unresolved source question: The complete stored individual review, label review, literature screening, conclusion and uncertainties were read. Targeted sections of original information were rechecked; no claim is made that all product information or full texts were completely revalidated.

Separately recorded findings

No separately substantiated finding for this drug–cannabinoid pair is recorded within the documented scope of review. This does not prove that no such study exists anywhere or that the combination is safe.

References and access status

[RLABEL_D0016] FONDAPARINUX SODIUM INJECTION, SOLUTION [ZYDUS PHARMACEUTICALS (USA) INC.]

Original source / bibliographic reference

Authors: Regulatory product information; respective marketing authorisation holder

Year: 2025

Source type: Product information / SmPC / US Prescribing Information

Source access – 23 October 2026: Source destination was accessible when checked.

Bibliographic attribution or source identity cross-checked.

Research as of 23 October 2026. Not all original full texts could be reviewed in full. Source accessibility and the strength of scientific evidence must be assessed separately. An accessible link does not establish medical approval; a bibliographic record with an abstract does not replace the original full text.

Drug search and explanation of the evidence · Guide: cannabinoids and medicines · Author and responsibility